A multicenter Phase III randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/Chemotherapy first line.
Study sites
- CHR Citadelle, Liège
- Clinique et maternité St. Elizabeth, Namur
- Grand hôpital de charleroi, Charleroi
- UZ Leuven, Leuven
